ISAM 2026 · Rotterdam, 2026

Emerging Fentanyl Analogues & Veterinary Tranquillisers

Urine drug screening gaps and preventative strategies in Alberta: what routine screens miss in a fast-changing drug supply, and how clinics can respond.

View slides (PDF)View e-poster (PDF)

Presented at: ISAM 2026
Location: Rotterdam
Year: 2026
Format: Talk + E-poster

1 / 12

Open PDF Download

Key messages

The drug supply is evolving faster than routine urine drug screening panels.
Many emerging substances, including nitazenes and medetomidine, are not detected on routine screens.
Medetomidine and xylazine can cause profound sedation that naloxone does not reverse.
Prevention combines clinical vigilance, targeted testing and surveillance.

Prepared for healthcare professionals. These presentations summarize clinical evidence and experience for colleagues. They are not advice about your own care; please speak with your physician.

More work

All presentations

Hepatitis CECHO+ Liver 9th Annual Congress, 2026

Treating HCV in an Urban Vulnerable Population

Bridging the gaps from diagnosis to cure: how an addiction medicine clinic, supported by ECHO+, brings hepatitis C treatment to people the system usually misses.

19 slides

View presentation

Addiction medicineISAM 2026 · Rotterdam, 2026

Kamini Use in Canada

An emerging substance of concern identified in Alberta: a herbal product that can carry opium-derived opioids, dependence and lead toxicity.

15 slidesE-poster

View presentation